GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Xultophy®

Company
Novo Nordisk A/S
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01676116

    The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

    Not yet reported Novo Nordisk A/S 438 participants Est. completion 2014-03-11 109 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02754817

    A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

    Novo Nordisk A/S 611 participants Est. completion 2016-10-20 5 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT03823339

    A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

    Novo Nordisk A/S 300 participants Est. completion 2020-12-14 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04666987

    A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy

    Novo Nordisk A/S 359 participants Est. completion 2023-02-10 28 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04838743

    GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.

    Novo Nordisk A/S 244 participants Est. completion 2022-10-26 42 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04952779

    Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

    Novo Nordisk A/S 750 participants Est. completion 2024-12-15 32 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT06113341

    A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

    Novo Nordisk A/S Est. completion 2026-03-02 19 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06449703

    A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects

    Not yet reported Tonghua Dongbao Pharmaceutical Co.,Ltd 44 participants Est. completion 2024-06-16 1 site
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT06559722

    A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

    Not yet reported Tonghua Dongbao Pharmaceutical Co.,Ltd 510 participants Est. completion 2026-02
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Xultophy®, Xultophy® (insulin degludec/liraglutide)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.